



Working for a tobacco-free Scotland

# ASH Scotland Smoking, alcohol and opioid dependence March 2012

## Key points:

- cigarettes are engineered to create and sustain dependence<sup>1</sup>
- nicotine is addictive, to a degree similar or in some respects exceeding addiction to drugs such as heroin or cocaine<sup>2</sup>
- that smokers continue to use tobacco in the face of serious health consequences attests to the addictiveness of nicotine
- rates of smoking amongst people who misuse drugs and alcohol are higher than in the general population
- it is wrong to assume that individuals with substance misuse problems do not want to quit smoking
- smoking cessation can be integrated into alcohol and drug misuse treatment without jeopardising recovery goals
- smoking cessation efforts may actually support long-term sobriety.

*This information briefing is for anyone involved in improving the health of people misusing alcohol and/or drugs who also smoke tobacco.*

## Introduction

In Scotland, 23% of all male deaths, 25% of all female deaths, 90% of lung cancer deaths in men aged over 35 years and 89% of lung cancer deaths in women aged over 35 can be attributed to tobacco use<sup>3</sup>. Twenty-two years of life are lost on average among men and women in middle age (35-69) from smoking<sup>4</sup>. As smoking causes such widespread harm to health, smoking cessation interventions (whether brief interventions, intensive individual or group support, or pharmacotherapies) are among the most cost-effective interventions available in preserving life<sup>5</sup>, even if an individual has smoked for many years.

Cigarette smoking amongst substance misusers is an important health risk within a population subgroup whose general health may already be compromised<sup>6</sup>. People who misuse substances tend to start smoking at a younger age and are also more likely to be heavy smokers, nicotine dependent, and experience greater difficulty with quitting<sup>7</sup>. Individuals with current or past substance misuse problems are also likelier to have psychiatric, cognitive or medical problems which require more specialised cessation interventions<sup>8</sup>.

Despite the serious risks which tobacco use poses, the benefits of smoking cessation have not always been a focus when engaging with substance misusers. Barriers which may contribute to this lack of focus include staff attitudes about and use of tobacco, lack of adequate staff training to address tobacco use, and limited tobacco dependence treatment resources<sup>9</sup>. However, a 2004 meta-analysis revealed initial success with smoking cessation at post-treatment, along with evidence that smoking cessation efforts may actually support long-term drug and alcohol sobriety<sup>10</sup>. In addition, clinical studies suggest that smoking cessation can be integrated substance misuse treatment without jeopardising recovery goals<sup>11 12 13</sup>.

Relative to other substances, tobacco is by far the most harmful and deadly. For example, in the United States more deaths are caused each year by tobacco use than by all deaths from human immunodeficiency virus (HIV), illegal drug use, alcohol use, motor vehicle injuries, suicides, and murders combined<sup>14</sup>. An 11-year retrospective study which followed up on individuals who received addiction treatment found that more than half of all deaths were tobacco-related<sup>15</sup>. In a 24-year prospective study of heroin misusers entering treatment, the death rate of smokers was found to be four times that of non-smokers, making smoking status a significant predictor for death in this population<sup>16</sup>. Until drug and alcohol services engage with tobacco dependence in their client groups (whether in residential or community settings), many will pass through the treatment system and overcome their 'primary' drug of misuse only to die prematurely from tobacco-related illnesses.

## Addictiveness of nicotine

*'a critical part of cigarette design is first ensuring that enough nicotine is available in the unsmoked rod, and then making sure that the design enables the smoker to get enough of the nicotine out to maintain his or her addiction.'*<sup>17</sup>

Tobacco products may be legal to use and easy to obtain but it would be a mistake to regard them as pharmacologically benign as they also meet the standard criteria for dependence-producing drugs<sup>18</sup>. In a landmark US legal ruling in 2006, the tobacco industry were found to have known for decades that they were 'in the drug business, and that cigarettes are drug delivery devices'<sup>19</sup>. The tobacco industry has deployed a vast array of technologies ranging from chemistry to particle physics to develop methods which manipulate nicotine delivery and absorption (eg adding levulinic acid, using filter tip ventilation, and regulating particle size). The modern cigarette is a precision-engineered product designed with a deliberately enhanced addiction risk<sup>20</sup>.

According to the Royal College of Physicians report "Nicotine Addiction in Britain", 'nicotine produces tolerance and dependence such that abstinence after appropriate dosing may result in withdrawal symptoms'. It appears that tobacco affects the same neural pathway, the mesolimbic dopamine system, as alcohol, opioids, cocaine, and marijuana<sup>21</sup>.

Yet tobacco products are not drugs of 'misuse', for smokers use them just as the manufacturers intended. This legitimate 'use' kills nearly six million people globally each year, of whom more than 5 million are users and ex-users and more than 600,000 are non-smokers exposed to second-hand smoke<sup>22</sup>. Is then tobacco-related death and disease a by-product of addiction?

## **Tobacco and alcohol**

Alcohol is responsible for one in twenty deaths in Scotland and mortality rates have doubled since the early 1990s<sup>23</sup>. A large-scale survey in the United States suggests that people who are dependent on alcohol are three times more likely than those in the general population to be smokers, and people who are dependent on tobacco are four times more likely than the general population to be dependent on alcohol<sup>24</sup>. Treatment of tobacco dependence in alcoholic smokers does not seem to cause excessive relapse to drinking and, in fact, stopping smoking may enhance abstinence from drinking<sup>25</sup>.

Alcohol and tobacco, alone or in combination, are associated with an increased risk of various cancers, including those of the upper aero-digestive tract and liver<sup>26</sup>. Combined alcohol and tobacco use can increase the risk of cancer of the oral cavity and throat (pharynx); the combined effect is such that heavy drinkers and smokers have 38 times the risk of abstainers from both products<sup>27</sup>. Similarly, 80 per cent of oesophageal squamous cell carcinomas in Europe and the Americas appear to be attributable to the synergistic effects of alcohol and tobacco<sup>28</sup>. There is clear evidence that for either alcohol or tobacco use, the risk of oesophageal cancer decreases rapidly, strongly and significantly with longer periods of abstinence, although the risk benefit of merely quitting alcohol drinking was delayed (>10 years of cessation) unless it was also accompanied by several years of smoking cessation<sup>29</sup>.

## **Opiate dependence and tobacco use**

There are almost 60,000 problem drug users in Scotland<sup>30</sup>. Anecdotally, most heroin users are believed to be smokers and in a 2011 study from Italy, smoking prevalence was reported to be 99.2%<sup>31</sup>.

## **Methadone maintenance and tobacco use**

Smoking prevalence among outpatient methadone users in the UK is reported to be 93%<sup>32</sup>. Methadone has been shown to increase cigarette smoking in a dose-dependent manner, whereas smoking/nicotine has been shown to increase methadone self-administration and reinforcing properties<sup>33</sup>.

Positive benefits of smoking reduction using NRT were found amongst a group of individuals with respiratory illness in a US methadone maintenance programme. An association between subjective short-term health changes and reduction in smoking was demonstrated<sup>34</sup>.

A recent journal article<sup>35</sup> reported that decreased intake of cigarette smoke can lead to a reduction in methadone metabolism, resulting in higher serum concentrations. This suggests that methadone users should be monitored for signs of methadone toxicity upon the start of smoking cessation, and the dose of methadone adjusted accordingly.

## Conclusion

Substance misusers have a higher burden of both mental and physical disease than the general population<sup>36</sup>. Up to three in four people using drugs have mental health problems, and up to one in two people with alcohol problems may have a mental health problem<sup>37</sup>, yet their physical health needs are less likely to be met. Surveys suggest that many people in drug or alcohol treatment programmes are interested in giving up smoking<sup>38</sup>. A meta-analysis of 18 studies suggests that addressing tobacco use in clients can improve their alcohol and other drug outcomes by an average of 25 per cent<sup>39</sup>, although it also noted that effects for smoking cessation were non-significant at long-term follow-up. Nevertheless, as previously noted, there is evidence to suggest that smoking cessation can be integrated into alcohol and drug misuse treatment without jeopardising recovery goals.

Approaches to reducing tobacco harm amongst those who misuse alcohol and drugs might include improved collaboration between health and addictions services, developing policy changes to promote addressing tobacco use, and providing increased financial support for specialised tobacco dependence treatment. Professionals working in substance misuse already have the knowledge and skills to support clients in dealing with their use of addictive substances and these skills should be directly applicable to treatment of tobacco. There may be a need for those working in substance misuse to have a better understanding of tobacco's harms and the substantial health benefits which smoking cessation confers. There is certainly a need for those who misuse alcohol and drugs to have improved access to smoking cessation support.

## Further support

- Scottish Drugs Forum [www.sdf.org.uk](http://www.sdf.org.uk)
- To find your nearest service see the Scottish Drugs Services Directory: [www.scottishdrugservices.com/sdd/homepage.htm](http://www.scottishdrugservices.com/sdd/homepage.htm)
- Alcohol Focus Scotland, 166 Buchanan Street, Glasgow G1 2LW. 0141 572 6700. [www.alcohol-focus-scotland.org.uk](http://www.alcohol-focus-scotland.org.uk)
- Support to give up smoking - phone free to Smokeline on 0800 84 84 84 (9am to 9pm, seven days a week). Smokeline advisers provide free advice and information for anyone who wants to stop smoking, or who wants to help someone else to quit. Smokeline also provides information about the free stop smoking services provided by every health board in Scotland. Or visit [www.canstopsmoking.com](http://www.canstopsmoking.com) and enter a postcode to find the nearest stop smoking service.

## Further information

### **Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology.**

Journal of Psychopharmacology 18(3) (2004) 293–335.

[www.bap.org.uk/pdfs/BAP\\_Guidelines.pdf](http://www.bap.org.uk/pdfs/BAP_Guidelines.pdf)

**Tobacco Treatment for Persons with Substance Use Disorders - A Toolkit for Substance Abuse Treatment Providers.** This easy-to-read, evidence-based toolkit was developed in Colorado, USA, by Tobacco Use Recovery Now! (TURN), a project of Signal Behavioral Health Network. It is free to download from:

<http://smokingcessationleadership.ucsf.edu/Downloads/Steppsudtoolkit.pdf>

The **Bringing Everyone Along** project (from the USA) has developed resources to assist health professionals to adapt their treatment services to the unique needs of tobacco users with mental health and substance use disorders. [www.tcln.org/bea/](http://www.tcln.org/bea/)

## References

- <sup>1</sup> Campaign for Tobacco-Free Kids U.S. District Judge Gladys Kessler's Final Opinion: Summary of Findings Against the Tobacco Industry. 2006  
[www.tobaccofreekids.org/content/what\\_we\\_do/industry\\_watch/doj/FinalOpinionSummary.pdf](http://www.tobaccofreekids.org/content/what_we_do/industry_watch/doj/FinalOpinionSummary.pdf) [Accessed 28.03.12]
- <sup>2</sup> Royal College of Physicians. Nicotine addiction in Britain - A report of the Tobacco Advisory Group of the Royal College of Physicians. 2000.  
<http://bookshop.rcplondon.ac.uk/details.aspx?e=131> [Accessed 28.03.12]
- <sup>3</sup> Boreham J. Male and female smoking-attributed deaths and total deaths, Scotland: 1995, 2008. Oxford: CTSU. 2010. [www.ctsu.ox.ac.uk/~tobacco/SMK\\_P5\\_6.pdf](http://www.ctsu.ox.ac.uk/~tobacco/SMK_P5_6.pdf) [Accessed 28.03.12]
- <sup>4</sup> NHS Health Scotland, ISD Scotland and ASH Scotland. An atlas of tobacco smoking in Scotland: estimated smoking prevalence and smoking-attributable deaths within Scotland. NHS Scotland/Scottish Public Health Observatory. 2007.  
[www.scotpho.org.uk/nmsruntime/saveasdialog.aspx?IID=3907&slD=3256](http://www.scotpho.org.uk/nmsruntime/saveasdialog.aspx?IID=3907&slD=3256) [Accessed 28.03.12]
- <sup>5</sup> Parrott S, Godfrey C, Raw M. Guidance for Commissioners on the Cost Effectiveness of Smoking Cessation Interventions. Thorax 1998, 53, S1–S38.  
[www.ncbi.nlm.nih.gov/pmc/articles/PMC1765918/](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1765918/) [Accessed 28.03.12]
- <sup>6</sup> Beynon CM, McVeigh J. The role of substance use in non-drug related deaths: a cross-sectional study of drug treatment clients in the North West of England. Journal of Substance Use, 2007, 12, 39-47. <http://informahealthcare.com/doi/abs/10.1080/14659890600824329> [Accessed 28.03.12]
- <sup>7</sup> Prochaska JJ, Delucchi K, Hall SM. A Meta-Analysis of Smoking Cessation Interventions With Individuals in Substance Abuse Treatment or Recovery. Journal of Consulting and Clinical Psychology, Vol. 72, No. 6, 1144–1156. [http://casat.unr.edu/docs/meta-analysis\\_JCCP2004.pdf](http://casat.unr.edu/docs/meta-analysis_JCCP2004.pdf) [Accessed 28.03.12]
- <sup>8</sup> Ibid.
- <sup>9</sup> Ziedonis, DM, Guydish J, Williams J, Steinberg M, Foulds J. Barriers and solutions to addressing tobacco dependence in addiction treatment programs. Alcohol Research & Health, 29, 228–235, 2006. [www.tobaccoprogram.org/pdf/228-235-g.pdf](http://www.tobaccoprogram.org/pdf/228-235-g.pdf) [Accessed 28.03.12]
- <sup>10</sup> Prochaska JJ, Delucchi K, Hall SM. A Meta-Analysis of Smoking Cessation Interventions With Individuals in Substance Abuse Treatment or Recovery. Journal of Consulting and

---

Clinical Psychology, Vol. 72, No. 6, 1144–1156. [http://casat.unr.edu/docs/meta-analysis\\_JCCP2004.pdf](http://casat.unr.edu/docs/meta-analysis_JCCP2004.pdf) [Accessed 28.03.12]

<sup>11</sup> Kalman D, Hayes K, Colby SM, Eaton CA, Rohsenow DJ, Monti PM. Concurrent versus delayed smoking cessation treatment for persons in early alcohol recovery. A Pilot Study. *Journal of Substance Abuse Treatment* 2001, 20, 233–238. [www.ncbi.nlm.nih.gov/pubmed/11516593](http://www.ncbi.nlm.nih.gov/pubmed/11516593) [Accessed 28.03.12]

<sup>12</sup> Reid MS et al. Smoking cessation treatment in community-based substance abuse rehabilitation programs. *Journal of Substance Abuse Treatment*, 2008, July;35(1):68-77. [www.ncbi.nlm.nih.gov/pubmed/17951021](http://www.ncbi.nlm.nih.gov/pubmed/17951021) [Accessed 28.03.12]

<sup>13</sup> Burling TA, Burling AS, Latini D. A controlled smoking cessation trial for substance-dependent inpatients. *Journal of Consulting and Clinical Psychology*. 2001 Apr;69(2):295-304. [www.ncbi.nlm.nih.gov/pubmed/11393606](http://www.ncbi.nlm.nih.gov/pubmed/11393606) [Accessed 28.03.12]

<sup>14</sup> Centers for Disease Control and Prevention (CDC). (2008) Health effects of cigarette smoking. [www.cdc.gov/tobacco/data\\_statistics/fact\\_sheets/health\\_effects/effects\\_cig\\_smoking/](http://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking/) [Accessed 28.03.12]

<sup>15</sup> Hurt RD, Offord KP, Croghan, IT, et al. Mortality following inpatient addictions treatment. Role of tobacco use in a communitybased cohort. *JAMA*. 1996;275(14):1097-1103. <http://jama.ama-assn.org/content/275/14/1097.abstract> [Accessed 28.03.12]

<sup>16</sup> Hser YI, Anglin D, Powers K. A 24-year follow-up of California narcotics addicts. *Archives of General Psychiatry*. 1993;50(7):577-584. <http://archpsyc.ama-assn.org/cgi/content/abstract/50/7/577> [Accessed 28.03.12]

<sup>17</sup> Former Philip Morris scientist cited in US District Court for the District of Columbia United States of America, Plaintiff, versus Philip Morris, USA, et al, defendants. Civil Action No. 99-2496 (GK). United States' Written Direct Examination of William A Farone, PhD. Submitted Pursuant to Order #471. 2004. Page 86 line13 onwards. [www.justice.gov/civil/cases/tobacco2/20040929%20Written%20Direct%20Testimony%20for%20William%20Farone%20PhD.pdf](http://www.justice.gov/civil/cases/tobacco2/20040929%20Written%20Direct%20Testimony%20for%20William%20Farone%20PhD.pdf) [Accessed 28.03.12]

<sup>18</sup> Royal College of Physicians. Nicotine addiction in Britain - A report of the Tobacco Advisory Group of the Royal College of Physicians. 2000. <http://bookshop.rcplondon.ac.uk/details.aspx?e=131> [Accessed 28.03.12]

<sup>19</sup> Tobacco Control Legal Consortium. 'The Verdict is In: Findings from United States v Philip Morris' Addiction. 2006. <http://publichealthlawcenter.org/sites/default/files/resources/tclcv-verdict-addiction.pdf> [Accessed 28.03.12]

<sup>20</sup> Henningfield JE, Benowitz NL, Connolly.G.N. (2004) Reducing tobacco addiction through tobacco product regulation. *Tobacco Control* 13: 132-135. <http://tobaccocontrol.bmj.com/content/13/2/132.full> [Accessed 28.03.12]

<sup>21</sup> Pierce RC, Kumaresan V. The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse. Boston: Boston University School of Medicine. *Neuroscience & Biobehavioral Reviews*, Volume 30, Issue 2, 2006, Pages 215–238. [www.sciencedirect.com/science/article/pii/S0149763405000692](http://www.sciencedirect.com/science/article/pii/S0149763405000692) [Accessed 28.03.12]

<sup>22</sup> World Health Organisation. Tobacco: factsheet No.339, July 2011, [www.who.int/mediacentre/factsheets/fs339/en/index.html](http://www.who.int/mediacentre/factsheets/fs339/en/index.html)

<sup>23</sup> Alcohol attributable mortality and morbidity: alcohol population attributable fractions for Scotland. Grant, Springbett and Graham, Information Services Division, National Health Service, 2009, [www.isdscotland.org/isd/5964.html](http://www.isdscotland.org/isd/5964.html) [Accessed 28.03.12]

<sup>24</sup> Grant BF, Hasin DS, Chou SP et al. Nicotine dependence and psychiatric disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Archives of General Psychiatry* 61:1107–1115, 2004. <http://archpsyc.ama-assn.org/cgi/content/abstract/61/11/1107> [Accessed 06.03.12]

<sup>25</sup> Hurt RD, Patten CA. Treatment of tobacco dependence in alcoholics. *Recent Developments in Alcoholism*, 2002, Volume 16, V, 335-359. [www.springerlink.com/content/j4g3214gjq733rw/](http://www.springerlink.com/content/j4g3214gjq733rw/) [Accessed 28.03.12]

<sup>26</sup> Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. *British Journal of Cancer* 85:1700–1705, 2001. <http://pubs.niaaa.nih.gov/publications/arh25-4/263-270.htm> [Accessed 28.03.12]

<sup>27</sup> Blot WJ et al., Smoking and drinking in relation to oral and pharyngeal cancer *Cancer Res*, 1988. 48(11): p. 3282-7. Cited by Cancer Research UK – Oral Cancer Risk Factors.

---

<http://info.cancerresearchuk.org/cancerstats/types/oral/riskfactors/oral-cancer-risk-factors#source67> [Accessed 28.03.12]

<sup>28</sup> Castellsagué, X et al. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. *International Journal of Cancer* 82:657–664, 1999. [www.ncbi.nlm.nih.gov/pubmed/10417762](http://www.ncbi.nlm.nih.gov/pubmed/10417762) [Accessed 28.03.12]

<sup>29</sup> Castellsagué, X et al. Smoking and drinking cessation and risk of esophageal cancer (Spain). *Cancer Causes and Control*, Volume 11, Number 9, 813-818. [www.springerlink.com/content/p675173514252366/](http://www.springerlink.com/content/p675173514252366/) [Accessed 28.03.12]

<sup>30</sup> Information Services Division Scotland .Estimating the prevalence of problem drug use in Scotland 2009/10. November 2011.

[www.drugmisuse.isdscotland.org/publications/local/prevalence2009\\_10.pdf](http://www.drugmisuse.isdscotland.org/publications/local/prevalence2009_10.pdf) [Accessed 02.03.12]

<sup>31</sup> Pajusco B et al. Tobacco smoking prevalence in a large sample of heroin users accessing rehabilitation. *Heroin Addiction and Related Clinical Problems* 2011; 13(1): 5-10. <http://europad.org/journal/2011/Pajusco%20et%20al%2013%281%292011.pdf> [Accessed 28.03.12]

<sup>32</sup> Kimber R, Arnsten J. A rationale and model for addressing tobacco dependence in substance abuse treatment. *Substance Abuse Treatment, Prevention, and Policy* 2006, 1:23. [www.substanceabusepolicy.com/content/1/1/23](http://www.substanceabusepolicy.com/content/1/1/23) [Accessed 28.03.12]

<sup>33</sup> Pajusco B et al. Tobacco smoking prevalence in a large sample of heroin users accessing rehabilitation. *Heroin Addiction and Related Clinical Problems* 2011; 13(1): 5-10. <http://europad.org/journal/2011/Pajusco%20et%20al%2013%281%292011.pdf> [Accessed 28.03.12]

<sup>34</sup> Stein MD, Weinstock CM, Herman DS, Anderson, J. Respiratory Symptom Relief Related to Reduction in Cigarette Use. *Journal of General Internal Medicine* 2005, 20, 889-894. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490242/> [Accessed 28.03.12]

<sup>35</sup> Wahawisan J et al. Methadone Toxicity Due to Smoking Cessation—A Case Report on the Drug-Drug Interaction Involving Cytochrome P450 Isoenzyme 1A2. *Annals of Pharmacotherapy*, June 2011 vol. 45 no. 6 e34. [www.theannals.com/content/45/6/e34.abstract](http://www.theannals.com/content/45/6/e34.abstract) [Accessed 28.03.12]

<sup>36</sup> Global Status Report on Alcohol and Health 2011, World Health Organization. [www.who.int/substance\\_abuse/publications/global\\_alcohol\\_report/en/index.html](http://www.who.int/substance_abuse/publications/global_alcohol_report/en/index.html) [Accessed 28.03.12]

<sup>37</sup> Mind the Gaps: Meeting the needs of people with co-occurring substance misuse and mental health problems, Scottish Executive, 2003. [www.scotland.gov.uk/Publications/2003/10/18358/28079](http://www.scotland.gov.uk/Publications/2003/10/18358/28079) [Accessed 28.03.12]

<sup>38</sup> Sullivan MA, Covey LS. Current perspectives on smoking cessation among substance abusers. *Current Psychiatry Reports* (2002). Volume: 4, Issue: 5, Pages: 388-396. [www.ncbi.nlm.nih.gov/pubmed/12230968](http://www.ncbi.nlm.nih.gov/pubmed/12230968) [Accessed 28.03.12]

<sup>39</sup> Prochaska JJ, Delucchi K, Hall SM. A Meta-Analysis of Smoking Cessation Interventions With Individuals in Substance Abuse Treatment or Recovery. *Journal of Consulting and Clinical Psychology*, Vol. 72, No. 6, 1144–1156. [http://casat.unr.edu/docs/meta-analysis\\_JCCP2004.pdf](http://casat.unr.edu/docs/meta-analysis_JCCP2004.pdf) [Accessed 28.03.12]

ASH Scotland, 8 Frederick Street, Edinburgh, EH2 2HB. 0131 225 4725  
E-mail: [enquiries@ashscotland.org.uk](mailto:enquiries@ashscotland.org.uk) [www.ashscotland.org.uk](http://www.ashscotland.org.uk)  
Action on Smoking & Health (Scotland) (ASH Scotland) is a registered Scottish charity (SC 010412) and a company limited by guarantee (Scottish company no 141711)